Antengene Corporation Limited

Company 6855.HK

Last mentioned: Mar 4, 2026

Timeline

  1. Clinical Filings Target

    Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.

  2. Investor Briefings

    Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.

  3. Investor Briefings

    Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact.

  4. Global License Agreement

    Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.

  5. Global License Agreement

    Antengene and UCB announce the $1.1B+ licensing deal for ATG-201.

  6. Regulatory Filings

    Planned submission of clinical trial applications for ATG-201 in China and Australia.

Stories mentioning Antengene Corporation Limited 2

pharma Bullish

UCB and Antengene Ink $1.1B Deal for CD19 Bispecific in Autoimmune Pivot

Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.

2 sources